Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Menard 2006 MDG (Continued)<br />
Blinding?<br />
All outcomes<br />
Incomplete outcome data addressed?<br />
All outcomes<br />
Yes ’All other study personnel were blinded<br />
to the treatment assignments, and patients<br />
not in<strong>for</strong>med of their treatment regimen’<br />
Yes Low losses to follow up in both groups<br />
(8.4% AS+AQ vs 4.8% AQ+SP)<br />
Free of selective reporting? Yes All WHO outcomes reported<br />
Free of other bias? Yes No other sources of bias identified<br />
Mens 2007 KEN<br />
Methods Trial design: An open label randomized controlled trial<br />
Follow up: Malaria film and haemoglobin level on days 0, 1, 2, 3, 7, 14, and 28, plus<br />
QT-NASBA <strong>for</strong> detection of sub-microscopic gametocytaemia<br />
Adverse event monitoring: Adverse events were recorded at each visit in the case record<br />
<strong>for</strong>m. An adverse event defined as any unfavourable and unintended sign.<br />
Participants Number: 146 randomized<br />
Inclusion criteria: Age 6 months to 12 years, axillary temp > 37.5 ºC or history of fever,<br />
P. falciparum mono-infection 1000 to 200,000/µl, in<strong>for</strong>med consent<br />
Exclusion criteria: Severe malaria, any other underlying illness<br />
Interventions 1. Dihydroartemisinin-piperaquine, fixed dose <strong>combination</strong>, 20 mg/160 mg tablets (<br />
Sigma-Tau)<br />
• 4 to 7 kg 1/2 tablet once daily <strong>for</strong> 3 days<br />
• 7 to 13 kg 1 tablet once daily <strong>for</strong> 3 days<br />
• 13 to 24 kg 2 tablets once daily <strong>for</strong> 3 days<br />
• 24 to 35 kg 4 tablets once daily <strong>for</strong> 3 days<br />
2. Artemether-lumefantrine, fixed dose <strong>combination</strong>, 20/120 mg tablets (Novartis)<br />
• 5 to 14 kg 1 tablet twice daily <strong>for</strong> 3 days<br />
• 15 to 24 kg 2 tablets twice daily <strong>for</strong> 3 days<br />
• 25 to 34 kg 3 tablets twice daily <strong>for</strong> 3 days<br />
All doses supervized and given with a glass of milk<br />
Outcomes 1. Recurrent parasitaemia at day 28, PCR adjusted and unadjusted<br />
2. Gametocyte prevalence during follow up<br />
3. Mean haemoglobin at day 28<br />
4. Adverse events<br />
Not included in this review:<br />
1. Fever clearance<br />
2. Parasite clearance<br />
Notes Country: Kenya<br />
Setting: Health centre<br />
Transmission: High transmission<br />
Resistance: Not reported<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
80